Blocking FDA approval of abortion pill could stifle innovation in the biopharma industry, experts say

The Justice Department will seek emergency intervention from the U.S. Supreme Court, it said Thursday.

That outcome would bring uncertainty to a regulatory framework that drugmakers rely on during the expensive and lengthy process of developing medications, they told CNBC. He said that kind of legal fight could have an effect similar to that of a drug's patent expiring, which reduces the medication's time on the market and typicallyA potential legal challenge is a "risk that effectively reduces the economic incentives of bringing drugs to the market," Lakdawalla said. He said it could cause companies and investors to funnel less money into drug research and development.

It takes at least 10 years on average for a new drug to reach the marketplace after its initial discovery, according to, the primary lobbying arm of the pharmaceutical industry. Clinical trials alone take six to seven years on average. Hastings was among the biopharma executives who first issued the open letter. He said the industry is "going to have trouble" if Kacsmaryk's ruling is ultimately upheld.

Law Law Latest News, Law Law Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Court Partially Halts Ruling Restricting Access to Abortion PillA hardline conservative judge suspended the FDA’s approval of the drug last Friday. hardline as jn radical comunist right wing
Source: thedailybeast - 🏆 307. / 63 Read more »

Clinical trial participant’s autopsy and brain exam stoke Alzheimer’s drug fearsThe brain of a woman who died after receiving a new Alzheimers disease drug has deepened some researchers’ concerns that lecanemab poses serious risks for patients. If I had alzheimers, I would probably want to take any risk to fight it, it's a horrible disease. Hopefully the drug is still promising. Is the drug as risky as… oh I don’t know…. Having Alzheimer’s? This is important research. Lecanemab is a great second step. I'm watching ProMISinc and their PMN310 closely. Impressive data at AD/PD 2023 showing higher selectivity and potentially lower ARIA-E risk due to less off-target binding $PMN
Source: NewsfromScience - 🏆 515. / 51 Read more »

The Comstock Act is no solution for pro-lifers or the FDA's bureaucratic rotIn a Friday afternoon news dump, Judge Matthew Kacsmaryk struck down the Food and Drug Administration's approval of mifepristone more than 20 years ago. Although a separate judge tried to oppose Kacsmaryk’s ruling, the FDA’s approval will inevitably face the highest court in the land. While some…
Source: dcexaminer - 🏆 6. / 94 Read more »